Youcare Pharmaceutical Group Co., Ltd. (SHA: 688658) announced that its subsidiaries Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. have received the Drug Clinical Trial Approval Notice from China’s National Medical Products Administration (NMPA) for YKYY036 Injection in obesity or overweight, while Beijing Youcare Kechuang also received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) (IND No. 183361) – clearing the company’s GalNAc‑conjugated siRNA candidate, which targets the novel metabolic gene INHBE, for clinical trials in both China and the United States.
Regulatory Milestone – NMPA (China)
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Drug Clinical Trial Approval Notice (IND) |
| Product | YKYY036 Injection |
| Acceptance No. | CXHL2601094 |
| Notice No. | 2026LP03110 |
| Indication | Obesity or overweight |
| Applicants | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.; Hangzhou Tianlong Pharmaceutical Co., Ltd. |
| Application Accepted | 9 Sep 2026 |
| Review Conclusion | Application meets drug registration requirements; clinical trials approved for the obesity or overweight indication |
Regulatory Milestone – FDA (United States)
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Approval Type | Study May Proceed Letter (IND clearance) |
| IND No. | 183361 |
| Product | YKYY036 Injection |
| Indication | Overweight or obesity |
| Applicant | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. |
| Review Conclusion | Clinical trial application approved; trials may proceed according to the submitted protocol |
Drug Profile & Mechanism of Action
- Molecule: YKYY036 Injection, a chemically synthesized double‑stranded siRNA drug independently developed by Beijing Youcare Kechuang and Hangzhou Tianlong Pharmaceutical.
- Delivery Platform: Conjugated with an N‑acetylgalactosamine (GalNAc) ligand – the industry‑standard targeted delivery chemistry that directs siRNA to hepatocytes via the asialoglycoprotein receptor, enabling potent, liver‑specific gene silencing.
- Target: Inhibin subunit beta‑E (INHBE) gene – via the RNA interference (RNAi) mechanism, YKYY036 binds and mediates degradation of INHBE mRNA, suppressing INHBE protein translation and thereby reducing production of the homodimeric protein Activin E.
- Mechanism Innovation: INHBE/Activin E represents a novel metabolic regulatory target; silencing it is positioned as a differentiated, mechanism‑of‑action‑based approach to weight management distinct from incretin‑based therapies.
Preclinical Evidence
- Pharmacological Activity: Preclinical studies showed YKYY036 exhibits significant pharmacological activity both in vitro and in vivo.
- Target Engagement: In multiple animal models – including INHBE humanized mice and non‑human primates – administration significantly reduced INHBE mRNA and Activin E protein levels.
- Safety: Repeat‑dose toxicity studies demonstrated a good safety and tolerability profile. Quantitative preclinical endpoints were not disclosed in the announcement.
Disease Landscape & Market Impact – Obesity
- Global Burden: Obesity is a highly prevalent chronic metabolic disease worldwide with a vast patient base and enormous unmet clinical need.
- Pain Points of Existing Therapies: Current treatments still face clinical challenges including weight rebound after discontinuation, gastrointestinal adverse effects and muscle loss – gaps that a novel‑mechanism RNAi therapy aims to address.
- Differentiated Positioning: By targeting the novel INHBE metabolic pathway, YKYY036 offers mechanism novelty and significant differentiation advantages versus established anti‑obesity drug classes.
- Global Clinical Layout: Securing dual clinical clearances from the NMPA and FDA establishes a global clinical development pathway for YKYY036 in the obesity indication, positioning Youcare Pharmaceutical among Chinese innovators pursuing worldwide weight‑management markets.
- Performance Impact: The company cautioned that the approvals represent a stage‑wise R&D achievement; given the long, multi‑stage and high‑risk nature of pharmaceutical development – spanning research, clinical trials, regulatory approval and commercialization – review timelines, trial results and future competitive dynamics carry substantial uncertainty, and the clearances are not expected to have a material impact on near‑term performance.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding YKYY036 Injection‘s clinical development in obesity or overweight, including trial timelines, clinical outcomes, regulatory approvals in China and the United States, and commercial expectations. Actual results may differ materially due to risks including the high‑technology, high‑risk nature of drug development, uncertainties in review and approval timing and results, subsequent research progress and evolving market competition.-Fineline Info & Tech
